JVI Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Usherwood, E. J.
Right arrow Articles by Woodland, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Usherwood, E. J.
Right arrow Articles by Woodland, D. L.

 Previous Article  |  Next Article 

Journal of Virology, September 2001, p. 8283-8288, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.8283-8288.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Latent Antigen Vaccination in a Model Gammaherpesvirus Infection

Edward J. Usherwood,1,dagger Kimberley A. Ward,1,Dagger Marcia A. Blackman,1 James P. Stewart,2 and David L. Woodland1,*

The Trudeau Institute, Saranac Lake, New York 12983,1 and The Laboratory for Clinical and Molecular Virology, Department of Veterinary Pathology, The University of Edinburgh, Edinburgh EH9 1QH, United Kingdom2

Received 3 April 2001/Accepted 4 June 2001

Vaccines that can reduce the load of latent gammaherpesvirus infections are eagerly sought. One attractive strategy is vaccination against latency-associated proteins, which may increase the efficiency with which T cells recognize and eliminate latently infected cells. However, due to the lack of tractable animal model systems, the effect of latent-antigen vaccination on gammaherpesvirus latency is not known. Here we use the murine gammaherpesvirus model to investigate the impact of vaccination with the latency-associated M2 antigen. As expected, vaccination had no effect on the acute lung infection. However, there was a significant reduction in the load of latently infected cells in the initial stages of the latent infection, when M2 is expressed. These data show for the first time that latent-antigen vaccination can reduce the level of latency in vivo and suggest that vaccination strategies involving other latent antigens may ultimately be successfully used to reduce the long-term latent infection.


* Corresponding author. Mailing address: The Trudeau Institute, 100 Algonquin Ave., Saranac Lake, NY 12983. Phone: (518) 891-3080, ext. 314. Fax: (518) 891-5126. E-mail: dwoodland{at}trudeauinstitute.org.

dagger Present address: Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, N.H.

Dagger Present address: University of Vermont, Department of Pathology, Burlington, VT 05405.


Journal of Virology, September 2001, p. 8283-8288, Vol. 75, No. 17
0022-538X/01/$04.00+0   DOI: 10.1128/JVI.75.17.8283-8288.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
J. Bacteriol. Mol. Cell. Biol. Microbiol. Mol. Biol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.